Regentis Biomaterials 提交 6-K,披露 GelrinC® 以色列独家经销协议新闻稿
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
Regentis Biomaterials Ltd. 在提交的 6-K 中披露,公司于 11 月 9 日发布新闻稿,宣布与 AMI Technologies 签署独家经销协议,以在以色列商业化 GelrinC®。该新闻稿作为附件 99.1 随文件提交。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2026
Commission file number: 001-42834
REGENTIS BIOMATERIALS LTD.
(Translation of registrant’s name into English)
60 Medinat Hayehudim Street, 4676652, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On November 9, 2026, Regentis Biomaterials Ltd. issued a press release entitled “Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC® in Israel.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The first, second and fourth paragraphs of the press release attached hereto as Exhibit 99.1 are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-298211), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release dated November 9, 2026. |
| 1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Regentis Biomaterials Ltd. | ||
| Date: November 9, 2026 | By: | /s/ Ori Gon |
| Name: | Ori Gon | |
| Title: | Chief Financial Officer | |
| 2 |
来源:SEC EDGAR · 本站存档